Nature:迄今全面的调控人类疾病的表观遗传学图谱 ​

2021-03-14 haibei MedSci原创

最近,研究人员发布了EpiMap,其包括了10,000个表观基因组图,跨越800个样本,可以被用来定义染色质状态,高分辨率增强子,增强子模块,上游调节器和下游靶基因。

全基因组关联研究(GWAS)已经成功地发现了超过10万个基因组位点,这些位点包含了与复杂性状和疾病表型相关的常见单核苷酸多态性(SNPs),为系统研究人类疾病的分子机制提供了一个非常重要的起点。然而,绝大多数的遗传关联仍然缺乏任何分子和细胞功能基础上的机制假说,因为超过90%的位点位于蛋白质编码外显子之外,并可能在基因调控区域与环路中扮演非编码作用,这个问题至今没有解决。

最近,研究人员发布了EpiMap,其包括了10,000个表观基因组图,跨越800个样本,可以被用来定义染色质状态,高分辨率增强子,增强子模块,上游调节器和下游靶基因

研究人员使用这个资源注释了30,000个遗传位点,这些位点与540个性状相关,并预测了性状相关的组织,在富集的组织增强子和候选组织特异性靶基因中的推定具有因果关系的核苷酸变异。

研究人员将多因素性状划分为具有不同功能富集和疾病合并模式的组织特异性致病因子,并揭示了单因素单向性和多因素多向性位点。得分最高的位点经常有多个预测的驱动变异,通过多个增强子与共同的靶基因、共同组织中的多个基因或多个基因和多个组织汇聚在一起,表明广泛的共生性。研究人员还利用该数据库,发现与冠心病(CAD)相关的表观遗传修饰的变化在脂肪组织,冠状动脉和肝脏以及许多其他组织中有富集

总是,该研究结果阐述了密集、丰富、高分辨率的表观基因组注释,对于研究复杂性状十分重要。

 

原始出处:

Carles A. Boix et al. Regulatory genomic circuitry of human disease loci by integrative epigenomics. Nature (2021). 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1885044, encodeId=a54a1885044ac, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed May 05 03:54:08 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843997, encodeId=d944184399ea6, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Fri Jan 21 05:54:08 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948293, encodeId=8e31948293bd, content=赞<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F5489153BD0D8C4CF80A1E42E63544BC/100, createdBy=d3542398499, createdName=ms6681647893676206, createdTime=Mon Mar 15 10:17:58 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948077, encodeId=b1f99480e78f, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Sun Mar 14 14:18:05 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948074, encodeId=796f9480e4d4, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F5489153BD0D8C4CF80A1E42E63544BC/100, createdBy=d3542398499, createdName=ms6681647893676206, createdTime=Sun Mar 14 13:12:46 CST 2021, time=2021-03-14, status=1, ipAttribution=)]
    2021-05-05 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1885044, encodeId=a54a1885044ac, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed May 05 03:54:08 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843997, encodeId=d944184399ea6, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Fri Jan 21 05:54:08 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948293, encodeId=8e31948293bd, content=赞<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F5489153BD0D8C4CF80A1E42E63544BC/100, createdBy=d3542398499, createdName=ms6681647893676206, createdTime=Mon Mar 15 10:17:58 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948077, encodeId=b1f99480e78f, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Sun Mar 14 14:18:05 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948074, encodeId=796f9480e4d4, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F5489153BD0D8C4CF80A1E42E63544BC/100, createdBy=d3542398499, createdName=ms6681647893676206, createdTime=Sun Mar 14 13:12:46 CST 2021, time=2021-03-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1885044, encodeId=a54a1885044ac, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed May 05 03:54:08 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843997, encodeId=d944184399ea6, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Fri Jan 21 05:54:08 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948293, encodeId=8e31948293bd, content=赞<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F5489153BD0D8C4CF80A1E42E63544BC/100, createdBy=d3542398499, createdName=ms6681647893676206, createdTime=Mon Mar 15 10:17:58 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948077, encodeId=b1f99480e78f, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Sun Mar 14 14:18:05 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948074, encodeId=796f9480e4d4, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F5489153BD0D8C4CF80A1E42E63544BC/100, createdBy=d3542398499, createdName=ms6681647893676206, createdTime=Sun Mar 14 13:12:46 CST 2021, time=2021-03-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1885044, encodeId=a54a1885044ac, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed May 05 03:54:08 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843997, encodeId=d944184399ea6, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Fri Jan 21 05:54:08 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948293, encodeId=8e31948293bd, content=赞<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F5489153BD0D8C4CF80A1E42E63544BC/100, createdBy=d3542398499, createdName=ms6681647893676206, createdTime=Mon Mar 15 10:17:58 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948077, encodeId=b1f99480e78f, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Sun Mar 14 14:18:05 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948074, encodeId=796f9480e4d4, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F5489153BD0D8C4CF80A1E42E63544BC/100, createdBy=d3542398499, createdName=ms6681647893676206, createdTime=Sun Mar 14 13:12:46 CST 2021, time=2021-03-14, status=1, ipAttribution=)]
    2021-03-14 carrotlyl

    厉害

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1885044, encodeId=a54a1885044ac, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed May 05 03:54:08 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843997, encodeId=d944184399ea6, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Fri Jan 21 05:54:08 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948293, encodeId=8e31948293bd, content=赞<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F5489153BD0D8C4CF80A1E42E63544BC/100, createdBy=d3542398499, createdName=ms6681647893676206, createdTime=Mon Mar 15 10:17:58 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948077, encodeId=b1f99480e78f, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Sun Mar 14 14:18:05 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948074, encodeId=796f9480e4d4, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/F5489153BD0D8C4CF80A1E42E63544BC/100, createdBy=d3542398499, createdName=ms6681647893676206, createdTime=Sun Mar 14 13:12:46 CST 2021, time=2021-03-14, status=1, ipAttribution=)]
    2021-03-14 ms6681647893676206

    0

相关资讯

JAHA:妊娠高血压增加产妇分娩后五年内发生冠心病、中风及死亡的风险

HDP与长期的心血管疾病和死亡风险有关,发生HDP的孕妇在分娩后应更密切地观察,并监测心血管危险因素。

EHJ盘点:2020年心血管疾病进展——冠心病预防

一起来看看心血管疾病领域大牛们的冠心病预防建议吧~

PLOS Medicine:多种血浆蛋白水平与冠心病患者心血管死亡相关

包括NTproBNP和cTnT-hs在内的多种血浆蛋白水平的分布可能与CHD患者心血管死亡风险增加相关。

JAHA:血清非酯化脂肪酸与冠心病死亡率和非致死性心肌梗死之间的关系

2个NEFAs(二高-γ-亚麻酸和反油酸)分别与CHD死亡率和非致死性MI之间呈正相关,提示其是CHD死亡和非致死性MI风险潜在的易感生物标志物。

JAHA:CTO患者行PCI治疗的益处在哪里?-在10年后

CTO病变经皮冠状动脉介入治疗(PCI) 在3年随访期内没有显示出心脑血管事件获益,那么行PCI术的意义在哪里?-JAHA:在10年后